This phase III study is evaluating how effective a new immunotherapy drug (IO102-IO103) is in combination with another immunotherapy drug (pembrolizumab), compared to pembrolizumab alone, in people with previously untreated, advanced melanoma.
This trial is treating patients with advanced or metastatic melanoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18)
Eligible participants will be randomly assigned to either the Experimental Arm or the Active Comparator Arm. All participants will receive pembrolizumab (200mg) administered intravenously every 3 weeks for a maximum of 35 cycles. Participants assigned to the Experimental Arm will also receive IO102-IO103 every three weeks with an additional dose given during the induction period on Day 8 of cycles 1 and 2. IO102-IO103 will thereafter be administered subcutaneously every 3 weeks during the maintenance period.
Recruiting Hospitals Read More